TMDX

TMDX

USD

TransMedics Group Inc. Common Stock

$121.176+0.866 (0.719%)

Prix en Temps Réel

Healthcare
Dispositifs médicaux
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$120.310

Haut

$125.220

Bas

$119.000

Volume

1.03M

Fondamentaux de l'Entreprise

Capitalisation Boursière

4.1B

Industrie

Dispositifs médicaux

Pays

United States

Statistiques de Trading

Volume Moyen

1.00M

Bourse

NGM

Devise

USD

Intervalle sur 52 Semaines

Bas $55Actuel $121.176Haut $145.5

Actualités Connexes

PR Newswire

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Voir plus
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and raises the price target from $142 to $147.

Voir plus
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147
Analyst Upgrades

Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140

Piper Sandler analyst Matt O'Brien maintains TransMedics Group with a Overweight and lowers the price target from $145 to $140.

Voir plus
Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140
Analyst Upgrades

Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target

Needham analyst Mike Matson upgrades TransMedics Group from Hold to Buy and announces $148 price target.

Voir plus
Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and maintains $142 price target.

Voir plus
Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target
Analyst Upgrades

Jefferies Initiates Coverage On TransMedics Group with Buy Rating, Announces Price Target of $145

Jefferies analyst Young Li initiates coverage on TransMedics Group with a Buy rating and announces Price Target of $145.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.